Role of immunophilins in recovery of erectile function after cavernous nerve injury

Journal of Sexual Medicine

Volumn 6, Issue SUPPL. 3, 2009, Pages 340-346

  Sezen, Sena F ^a   Lagoda, Gwen ^a   Burnett, Arthur L ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Cavernous nerve; Crush injury; Erectile dysfunction; FKBP; Nitric oxide

Indexed keywords

1 (3,3 DIMETHYL 1,2 DIOXOPENTYL) 2 PYRROLIDINECARBOXYLIC ACID 3 (3 PYRIDYL)PROPYL ESTER; FK 1706; FK 506 BINDING PROTEIN; FK 506 BINDING PROTEIN 38; FK 506 BINDING PROTEIN 65; GPI 1485; IMMUNOPHILIN; IMMUNOSUPPRESSIVE AGENT; NITRIC OXIDE; PLACEBO; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; CAVERNOUS NERVE INJURY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; ERECTILE DYSFUNCTION; HUMAN; LIGAND BINDING; MOLECULAR BIOLOGY; MUSCLE REINNERVATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PENIS ERECTION; PERIPHERAL NERVE INJURY; PRIORITY JOURNAL; PROSTATE; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION;

EID: 61849095217     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2008.01193.x     Document Type: Conference Paper

References (43)

1. Montorsi F, Burnett AL. Erectile dysfunction after radical prostatectomy. BJU Int 2004; 93: 1-2.
2. Walsh PC, Marschke P, Ricker D, Burnett AL. Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. Urology 2000; 55: 58-61.
3. Marks AR. Cellular functions of immunophilins. Physiol Rev 1996; 76: 631-49.
4. Snyder SH, Lai MM, Burnett PE. Immunophilins in the nervous system. Neuron 1998; 21: 283-94.
5. Rulten SL, Kinloch RA, Tateossian H, Robinson C, Gettins L, Kay JE. The human FK506-binding proteins: Characterization of human FKBP19. Mamm Genome 2006; 17: 322-31.
6. Galat A. Peptidylproline cis-trans-isomerases: Immunophilins. Eur J Biochem 1993; 216: 689-707.
7. Galat A. A note on clustering the functionally-related paralogues and orthologues of proteins: A case of the FK506-binding proteins (FKBPs). Comput Biol Chem 2004; 28: 129-40.
8. Aghdasi B, Ye K, Resnick A, Huang A, Ha HC, Guo X, Dawson TM, Dawson VL, Snyder SH. FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle. Proc Natl Acad Sci U S A 2001; 98: 2425-30.
9. Davies TH, Sanchez ER. FKBP52. Int J Biochem Cell Biol 2005; 37: 42-7.
10. Yong W, Yang Z, Periyasamy S, Chen H, Yucel S, Li W, Lin LY, Wolf IM, Cohn MJ, Baskin LS, Sánchez ER, Shou W. Essential role for Co-chaperone FKBP52 but not FKBP51 in androgen receptor-mediated signaling and physiology. J Biol Chem 2007; 282: 5026-36.
11. Patterson CE, Schaub T, Coleman EJ, Davis EC. Developmental regulation of FKBP65. An ER-localized extracellular matrix binding-protein. Mol Biol Cell 2000; 11: 3925-35.
12. Edlich F, Weiwad M, Erdmann F, Fanghanel J, Jarczowski F, Rahfeld JU, Fischer G. Bcl-2 regulator FKBP38 is activated by Ca2+/calmodulin. EMBO J 2005; 24: 2688-99.
13. Kang CB, Feng L, Chia J, Yoon HS. Molecular characterization of FK-506 binding protein 38 and its potential regulatory role on the anti-apoptotic protein Bcl-2. Biochem Biophys Res Commun 2005; 337: 30-8.
14. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramman R, Jain A. FK 506 for liver, kidney, and pancreas transplantation. Lancet 1989; 2: 1000-4.
15. Huang S, Bjornsti MA, Houghton PJ. Rapamycins: Mechanism of action and cellular resistance. Cancer Biol Ther 2003; 2: 222-32.
16. Weiwad M, Edlich F, Kilka S, Erdmann F, Jarczowski F, Dorn M, Moutty MC, Fischer G. Comparative analysis of calcineurin inhibition by complexes of immunosuppressive drugs with human FK506 binding proteins. Biochemistry 2006; 45: 15776-84.
17. Steiner JP, Dawson TM, Fotuhi M, Glatt CE, Snowman AM, Cohen N, Snyder SH. High brain densities of the immunophilin FKBP colocalized with calcineurin. Nature 1992; 358: 584-7.
18. Lyons WE, Steiner JP, Snyder SH, Dawson TM. Neuronal regeneration enhances the expression of the immunophilin FKBP-12. J Neurosci 1995; 15: 2985-94.
19. Lyons WE, George EB, Dawson TM, Steiner JP, Snyder SH. Immunosuppressant FK506 promotes neurite outgrowth in cultures of PC12 cells and sensory ganglia. Proc Natl Acad Sci U S A 1994; 91: 3191-5.
20. Gold B, Katoh K, Storm-Dickerson T. The immunosuppressant FK506 increases the rate of axonal regeneration in rat sciatic nerve. J Neurosci 1995; 15: 7509-16.
21. Freeman EE, Grosskreutz CL. The effects of FK506 on retinal ganglion cells after optic nerve crush. Invest Ophthalmol Vis Sci 2000; 41: 1111-5.
22. Bavetta S, Hamlyn PJ, Burnstock G, Lieberman AR, Anderson PN. The effects of FK506 on dorsal column axons following spinal cord injury in adult rats: Neuroprotection and local regeneration. Exp Neurology 1999; 158: 382-93.
23. Sezen SF, Hoke A, Burnett AL, Snyder SH. Immunophilin ligand FK506 is neuroprotective for penile innervation. Nat Med 2001; 7: 1073-4.
24. Burnett AL, Becker RE. Immunophilin ligands promote penile neurogenesis and erection recovery after cavernous nerve injury. J Urol 2004; 171: 495-500.
25. Mulhall JP, Muller A, Donohue JF, Golijanin D, Tal R, Akin-Olugbade Y, Kobylarz K, Cohen-Gould L, Bennett NE, Scardino P. FK506 and erectile function preservation in the cavernous nerve injury model: Optimal dosing and timing. J Sex Med 2008; 5: 1334-44.
26. ClinicalTrials.gov. A safety and efficacy study of Prograf in the prevention of erectile dysfunction after radical prostatectomy. Available at: http://clinicaltrials.gov/ct2/show/NCT00106392 (accessed 2008).
27. Valentine H, Chen Y, Guo H, McCormick J, Wu Y, Sezen SF, Hoke A, Burnett AL, Steiner JP. Neuroimmunophilin ligands protect cavernous nerves after crush injury in the rat: New experimental paradigms. Eur Urol 2007; 51: 1724-31.
28. Bella AJ, Hayashi N, Carrion RE, Price R, Lue TF. FK1706 enhances the recovery of erectile function following bilateral cavernous nerve crush injury in the rat. J Sex Med 2007; 4: 341-6.
29. Hayashi N, Minor TX, Carrion R, Price R, Nunes L, Lue TF. The effect of FK1706 on erectile function following bilateral cavernous nerve crush injury in a rat model. J Urol 2006; 176: 824-9.
30. ClinicalTrials.gov. Evaluate the effects of GPI 1485 on erectile function following bilateral nerve-sparing prostatectomy. Available at: http://clinicaltrials.gov/ct/show/NCT00090376 (accessed 2008).
31. Ruan B, Pong K, Jow F, Bowlby M, Crozier RA, Liu D, Liang S, Chen Y, Mercado ML, Feng X, etal. Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities. Proc Natl Acad Sci U S A 2008; 105: 33-8.
32. Shirane M, Ogawa M, Motoyama J, Nakayama KI. Regulation of apoptosis and neurite extension by FKBP38 is required for neural tube formation in the mouse. Genes Cells 2008; 13: 635-51.
33. Keilhoff G, Fansa H, Wolf G. Differences in peripheral nerve degeneration/regeneration between wild-type and neuronal nitric oxide synthase knockout mice. J Neurosci Res 2002; 68: 432-41.
34. Keilhoff G, Fansa H, Wolf G. Neuronal nitric oxide synthase is the dominant nitric oxide supplier for the survival of dorsal root ganglia after peripheral nerve axotomy. J Chem Neuroanat 2002; 24: 181-7.
35. Farooque M, Isaksson J, Olsson Y. Improved recovery after spinal cord injury in neuronal nitric oxide synthase-deficient mice but not in TNF-alpha-deficient mice. J Neurotrauma 2001; 18: 105-14.
36. Bayir H, Kagan VE, Clark RS, Janesko-Feldman K, Rafikov R, Huang Z, Zhang X, Vagni V, Billiar TR, Kochanek PM. Neuronal NOS-mediated nitration and inactivation of manganese superoxide dismutase in brain after experimental and human brain injury. J Neurochem 2007; 101: 168-81.
37. Hurt KJ, Sezen SF, Champion HC, Crone JK, Palese MA, Huang PL, Sawa A, Luo X, Musicki B, Snyder SH, Burnett AL. Alternatively spliced neuronal nitric oxide synthase mediates penile erection. Proc Natl Acad Sci U S A 2006; 103: 3440-3.
38. Stamler JS, Lamas S, Fang FC. Nitrosylation. The prototypic redox-based signaling mechanism. Cell 2001; 106: 675-83.
39. Lagoda G, Jin L, Lehrfeld TJ, Liu T, Burnett AL. FK506 and sildenafil promote erectile function recovery after cavernous nerve injury through antioxidative mechanisms. J Sex Med 2007; 4: 908-16.
40. Tanaka K, Yoshioka M, Miyazaki I, Fujita N, Ogawa N. GPI1046 prevents dopaminergic dysfunction by activating glutathione system in the mouse striatum. Neurosci Lett 2002; 321: 45-8.
41. Tanaka K, Fujita N, Yoshioka M, Ogawa N. Immunosuppressive and non-immunosuppressive immunophilin ligands improve H(2)O(2)-induced cell damage by increasing glutathione levels in NG108-15 cells. Brain Res 2001; 889: 225-8.
42. Tanaka K, Fujita N, Higashi Y, Ogawa N. Neuroprotective and antioxidant properties of FKBP-binding immunophilin ligands are independent on the FKBP12 pathway in human cells. Neurosci Lett 2002; 330: 147-50.
43. Lagoda G, Sezen SF, Liu T, Hoke A, Burnett AL. FK506-binding protein localizations in human penile innervation. BJU Int 2008; 101: 604-9.